As of September 30, TFF Pharmaceuticals reported cash and cash equivalents of $13.1M. Additionally, the company received $0.8M from the Australian Taxation Office in October "We have recently announced positive proof of concept data from two patients in our TFF Voriconazole compassionate use program," said Glenn Mattes, CEO of TFF Pharmaceuticals. "We believe these data demonstrate our ability to transform the value of our technology platform into meaningful clinical results for patients. In our view, Thin Film Freezing has the potential to become a cornerstone technology for delivering next-generation, dry powder therapeutics to patients more safely and accurately. We are encouraged by the results of the two recent TFF VORI compassionate use cases and look forward to additional data from our ongoing clinical programs and external collaborations."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on TFFP:
- TFF Pharmaceuticals to Hold Third Quarter 2022 Financial and Business Results Conference Call on November 14, 2022
- TFF Pharma Tanks After Delay in the Release of Clinical Data
- TFF Pharmaceuticals Announces Second Patient Successfully Treated with Voriconazole Inhalation Powder Through Compassionate Use Program
- TFF Pharmaceuticals Announces Presentation of Data Featuring Applications of Thin Film Freezing Technology at AAPS PharmSci 360 Meeting
- TFF Pharmaceuticals to Participate in the Roth Inaugural Healthcare Opportunities Conference
